The mds Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the mds Hub cannot guarantee the accuracy of translated content. The mds and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View mds content recommended for you
Visual abstract | Enasidenib as monotherapy and in combination with azacitidine for patients with IDH2-mutated MDS: results from a phase II study
The MDS Hub is pleased to present a visual abstract representing key data from a phase II clinical trial (NCT03383575) evaluating enasidenib, both in combination with azacitidine and as monotherapy in patients with high-risk IDH2-mutated MDS. The safety and efficacy of enasidenib has been previously reported by the MDS Hub.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
